Leading Academic Medical Centers Join Biological Dynamics’ ExoLuminate™ Study, Expanding Enrollment for Early Pancreatic Cancer Detection

2023-12-05

SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.

'Currently, there is no standard early detection test for pancreatic cancer, resulting in an unmet need for innovative solutions to help solve this challenging disease'

Known as a “silent killer,” approximately 80% of pancreatic cancer patients discover the disease in late stages when it has already spread and cannot be surgically removed. Of these patients, almost none are still living five years after diagnosis. However, the 5-year survival rate increases to at least 44% if the disease is discovered when the cancer is still localized and diagnosed in the early stages.1 Biological Dynamics’ ExoVita Pancreas assay has demonstrated the ability to detect cancer at stages I and II with 93% sensitivity and 91% specificity.

“Currently, there is no standard early detection test for pancreatic cancer, resulting in an unmet need for innovative solutions to help solve this challenging disease,” said Harmeet Dhani, MD, MSc, Medical Director at Biological Dynamics and Principal Study Investigator. “Collaborating with these cutting-edge institutions expands our work with some of the top cancer researchers in the world. Together, we can significantly impact outcomes for individuals at risk of pancreatic cancer.”

The ExoLuminate Study (NCT05625529) will demonstrate the performance of the ExoVita Pancreas assay for early detection of PDAC in individuals with high risk of pancreatic cancer, as compared to the current standard-of-care methods of surveillance. These high-risk factors can include genetic mutations, strong family history, the presence of cystic lesions in the pancreas, and pancreatitis. The new study sites will bring another wave of subject enrollment following the recent collaboration with the PRECEDE Consortium, which is accelerating enrollment of at least 5,000 subjects and approximately 30,000 specimens into the ExoLuminate Study.

“By working with these premier research institutions, as well as with the PRECEDE consortium, we have an incredible opportunity to build momentum for our ExoLuminate Study. This is a testament to the work we are doing with our ExoVerita™ platform to further substantiate the importance of exosomes and extracellular vesicles in clinical care,” said Paul R. Billings, MD, PhD, CEO and Director of Biological Dynamics. “As we continue to focus on developing exosome-based solutions that will power the next generation of assays for earlier disease detection, these collaborations are another significant step toward delivering effective treatments to individuals faced with an increased risk of developing challenging diseases like pancreatic cancer.”

About Biological Dynamics

Biological Dynamics, Inc. is a leader in exosome-isolation technology committed to improving global health outcomes by identifying early stage diseases. Its Verita™ platform offers a simple and automated workflow to enrich for exosomes, powering advanced detection tests for some of the most challenging diseases. Biological Dynamics’ ExoVita™ assays utilize the Verita platform to enable reliable surveillance and early cancer detection to help enhance and extend lives. The Company operates a CAP-accredited, CLIA-certified clinical laboratory in San Diego, California. Learn more at www.BiologicalDynamics.com.

References: